Previous 10 | Next 10 |
Summary Today's market X-ray shows the returns for each index, asset class, sector, and so on, since the recent low point on June 16th. Of the global indices, US small caps are in the lead, followed by the NASDAQ. High beta stocks are the most preferred factors since June 16. ...
Summary Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma...
Summary The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry’s long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025. ...
Summary TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs. Headwinds and risks involved. Overview CytoDyn Inc. (CYDY) is a Vanc...
Summary Toripalimab approval will be decided for Coherus at the end of December. Cimerli approval has pushed up the stock. However, the tori PDUFA is the major catalytic event here. It is interesting to see that despite its foray into original R&D through a Chine...
Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR. Though early Intellia has the potential to show better clinical outcomes in patients with ATTR. For years, patient...
ImmunoGen announced that it will receive the FDA decision for mirvetuximab on November 28th. The deal with Oxford BioTechnologies will support further growth. ImmunoGen remains robust from a financial point of view. Two weeks ago, the leading biotech company ImmunoGen, I...
Why health care stocks may outperform the broader market in the long run. Is now the time to consider health care stocks? Why health care is still a good way for investors to play defense. Greg Bonnell: Many health care stocks are down from the highs put in e...
Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of Im...
BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. The global market opportunity for Duchenne Muscular Dystrophy is expected to reach $4.11 billion by 2023. Sarept...
News, Short Squeeze, Breakout and More Instantly...
First Trust Amex Biotech Index Fund Company Name:
FBT Stock Symbol:
NYSE Market:
2024-07-21 12:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-01 10:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 11:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...